Food News and Research

RSS

The prevalence of gluten-sensitive enteropathy in iron-deficient anemia patients

Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy due to food gluten intolerance in genetically predisposed people.

1 Jan 2009

Final FDA approval for generic version of antiretroviral Zerit capsules

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. Food and Drug Administration (FDA) on December 29, for its Abbreviated New Drug Application (ANDA) for Stavudine Capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.

1 Jan 2009

FDA to review prasugrel for acute coronary syndromes

Daiichi Sankyo Company, Limited and Eli Lilly and Company has confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009.

1 Jan 2009

Risk takers do so because their brains are less able to process dopamine

According to scientists risk takers and drug abusers behave the way they do because their brains are less able to process dopamine.

30 Dec 2008

Watson Pharmaceuticals receives FDA approval for generic Mircette

Watson Pharmaceuticals, Inc. has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg / 0.02 mg.

30 Dec 2008

Salix Pharmaceuticals receives FDA response for Balsalazide tablet

Salix Pharmaceuticals, Ltd. has announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

30 Dec 2008

Pegloticase BLA filing accepted for priority review by FDA

Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.

30 Dec 2008

FDA issues complete response letter to Ipsen for Dysport BLA

Ipsen has announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.

30 Dec 2008

Diet high in inorganic phosphates increases risk of lung cancer

New research in an animal model suggests that a diet high in inorganic phosphates, which are found in a variety of processed foods including meats, cheeses, beverages, and bakery products, might speed growth of lung cancer tumors and may even contribute to the development of those tumors in individuals predisposed to the disease.

30 Dec 2008

High-fat diet can disrupt our biological clock

Indulgence in a high-fat diet can not only lead to overweight because of excessive calorie intake, but also can affect the balance of circadian rhythms - everyone's 24-hour biological clock, Hebrew University of Jerusalem researchers have shown.

29 Dec 2008

FDA approves injectable drug degarelix for advanced prostate cancer

The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

29 Dec 2008

How mirror neurons allow us to learn and socialize by going through the motions in the head

The old adage that we can only learn how to do something by trying it ourselves may have to be revised in the light of recent discoveries in neuroscience.

21 Dec 2008

FDA issues complete response to biologics license application for ustekinumab

Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab.

21 Dec 2008

Poeple who eat out often more likely to be obese

In small towns in the Midwestern United States, people who eat out often at buffets and cafeterias and who perceive their community to be unpleasant for physical activity are more likely to be obese.

21 Dec 2008

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

21 Dec 2008

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008

Neuralstem files IND for amyotrophic lateral sclerosis stem cell trial

Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

18 Dec 2008

IMRIS receives FDA clearance for 3 Tesla IMRISneuro

IMRIS Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's 3 Tesla IMRISneuro for sale in the U.S. IMRISneuro is now available with either a 1.5 Tesla (1.5T) or a 3 Tesla (3T) magnet.

18 Dec 2008

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.

18 Dec 2008

Watson Pharmaceuticals receives FDA approval for generic Razadyne ER capsules

Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for galantamine hydrobromide extended-release capsules, eq. to 8 mg, 16 mg and 24 mg (galantamine base).

17 Dec 2008